

**Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin)
Recombinant Antibody
Catalog # APR10273****Specification****Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	P20138
Reactivity	Rat, Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin) - Additional Information**Target/Specificity**

Siglec-3 / CD33

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

#N/A

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in 100mM Pro-Ac, 20mM Arg, pH5.0, without preservative.This antibody is purified through a protein A column.

Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin) - Protein Information**Name** CD33**Synonyms** SIGLEC3**Function**

Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:11320212, PubMed:15597323). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872). Upon engagement of ligands such as C1q or sialylated glycoproteins, two immunoreceptor

tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed: [10887109](http://www.uniprot.org/citations/10887109), PubMed: [28325905](http://www.uniprot.org/citations/28325905)). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed: [10206955](http://www.uniprot.org/citations/10206955), PubMed: [10556798](http://www.uniprot.org/citations/10556798), PubMed: [10887109](http://www.uniprot.org/citations/10887109)). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed: [10206955](http://www.uniprot.org/citations/10206955), PubMed: [10887109](http://www.uniprot.org/citations/10887109)). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed: [15597323](http://www.uniprot.org/citations/15597323)).

Cellular Location

[Isoform CD33M]: Cell membrane; Single-pass type I membrane protein

Tissue Location


Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells

Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin) - Images



Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin) on SDS-PAGE under reducing

(R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab ozogamicin) is more than 95% ,determined by SEC-HPLC.